Provided by Tiger Fintech (Singapore) Pte. Ltd.

Brainstorm Cell Therapeutics

1.06
-0.0300-2.75%
Post-market: 1.05-0.0100-0.94%19:58 EDT
Volume:422.21K
Turnover:449.67K
Market Cap:8.42M
PE:-0.46
High:1.10
Open:1.08
Low:1.02
Close:1.09
Loading ...

BrainStorm files to sell 2.76M shares of common stock for holders

TIPRANKS
·
26 Jun

Brainstorm Cell Therapeutics Files Prospectus for Offer & Sale of up to 2.8 Mln Shares of Common Stock by Selling Stockholder - SEC Filing

THOMSON REUTERS
·
26 Jun

Brainstorm Cell Therapeutics Inc. Conducted Annual Stockholders Meeting Virtually

Reuters
·
26 Jun

Promising Survival Data and Regulatory Progress Bolster Buy Rating for Brainstorm Cell Therapeutics

TIPRANKS
·
17 Jun

BrainStorm Cell Therapeutics Announces Promising New Survival Data from Expanded Access Program for ALS Treatment NurOwn®

Reuters
·
16 Jun

Brainstorm Announces New Survival Data From Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years With Nurown®

THOMSON REUTERS
·
16 Jun

BrainStorm signs LOI with Minaris to manufacture NurOwn

TIPRANKS
·
27 May

BrainStorm Cell Therapeutics Partners with Minaris to Advance Phase 3b ALS Clinical Trial for NurOwn®

Reuters
·
27 May

Brainstorm Secures Key Manufacturing Partnership With Minaris for Upcoming Nurown® Phase 3B ALS Clinical Trials

THOMSON REUTERS
·
27 May

Brainstorm Cell Therapeutics Reports Q1 2025 Financials

TIPRANKS
·
20 May

Brainstorm Cell Therapeutics: Progress and Challenges in ALS Trial

TIPRANKS
·
20 May

Top Midday Gainers

MT Newswires Live
·
20 May

BrainStorm Cleared by FDA to Begin Phase 3b Trial of NurOwn for ALS

MT Newswires Live
·
19 May

BrainStorm Cell Therapeutics Inc. Receives FDA Clearance to Launch Phase 3b Trial of NurOwn® for ALS

Reuters
·
19 May

Brainstorm Receives FDA Clearance to Initiate Phase 3B Trial of Nurown® for ALS

THOMSON REUTERS
·
19 May

BrainStorm Cell Therapeutics Reports Q1 2025 Net Loss of $2.9M and EPS Improvement to $0.45

Reuters
·
16 May

Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Brainstorm Cell Q1 EPS $(0.45) Beats $(0.97) Estimate

Benzinga
·
16 May

Brainstorm Cell Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview

Reuters
·
13 May

Brainstorm Cell Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview

Reuters
·
09 May